Abstract
Background. A possible approach to overcome the limitation of SARS-CoV-2 tests availability is the usage of rapid diagnostic tests. In this study, we focused on the potential effectiveness of a rapid SARS-CoV-2 antigen assay in specifically detecting patients with high nasopharyngeal viral load.Methods. Fujirebio Espline SARS-CoV-2 rapid antigen test was used for analyzing nasopharyngeal samples collected from a series of consecutive patients who were positive by molecular testing at the Pederzoli Hospital (Peschiera del Garda, Verona, Italy) between 5 and 19 April, 2021. Molecular testing was carried out with Altona Diagnostics RealStar® SARSCoV-2 RT-PCR Kit, detecting SASR-CoV-2 S and E genes.Results. The final study population consisted of 174 patients (mean age, 43±19 years; 80 women, 46%). A total number of 47/174 samples tested positive with Fujirebio Espline SARS-CoV-2, equating to 27% positive percent agreement (95% CI, 21-34%). The area under the curve of Fujirebio Espline SARS-CoV-2 for identifying samples with higher risk of infectivity was 0.89 (95% CI, 0.83 to 0.94; pConclusion. Fujirebio Espline SARS-CoV-2 rapid antigen test displays excellent specificity for identifying potentially infectious patients, though subjects testing negative may still retain low infective potential.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
